New drug cocktail aims to stop liver cancer from coming back

NCT ID NCT07160361

Not yet recruiting Disease control Sponsor: Second Affiliated Hospital of Xi'an Jiaotong University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether giving a combination of two drugs—lenvatinib and losartan—after surgery can lower the chance of liver cancer returning in patients whose tumors show 'tumor budding,' a sign of aggressive disease. The drugs work by breaking down collagen barriers around cancer cells and targeting the cells directly. The trial will follow 56 patients for two years to see how many have their cancer come back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib and losartan
What this could lead to: If successful, this combination could offer a new way to reduce the risk of liver cancer returning after surgery for patients with tumor budding.
What could go wrong: This is a small, early-phase study with only 56 participants, so results may not apply to everyone. The combination may cause side effects or fail to prevent recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR

More trials for these conditions

Other studies related to the condition(s) this trial covers.